Understanding challenges for ultra-rare lysosomal storage disorders: Patient and caregiver experience of care and support through the disease journey

Eva M Raebel1, Steve Cotterell1, Sophie Thomas2
1. Rare Disease Research Partners, Amersham, UK; 2. MPS Society, Amersham, UK.

Background
Lysosomal storage disorders (LSD) are autosomal recessive lysosomal storage conditions, caused by lysosomal enzyme deficiencies, that are life-limiting and characterised by progressive neurological and cognitive deterioration, including other body systems.1,2

The exact prevalence of ultra-rare LSDs is difficult to determine but is estimated at <1 in a million3

Ultra-rare disorders have a profound impact on patients and their caregivers but information about the experience of care and support received by patients and their families during the disease journey is limited.

Objectives
• To gain an understanding of patient and caregiver experiences of living with an ultra-rare lysosomal storage disorder
• To gather insights into how best to support these patients and their families

Methods
Parents/caregivers of members with eligible ultra-rare disorders (Table 1) were invited to take part.

Telephone semi-structured interviews were conducted between June-September 2020. Qualitative data collected included questions about their experience with the care and support received since diagnosis.

Responses were analysed by applying an inductive thematic-content approach.

Results

Patient demographics

<table>
<thead>
<tr>
<th>Disorder</th>
<th>Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fucosidosis</td>
<td>4</td>
</tr>
<tr>
<td>GM I Gangliosidosis</td>
<td>1</td>
</tr>
<tr>
<td>LAL-D (Lysosomal acid lipase deficiency)</td>
<td>2</td>
</tr>
<tr>
<td>ML II (Mucolipidosis II, cell disease)</td>
<td>3</td>
</tr>
<tr>
<td>MSD (Multiple sulfatase deficiency)</td>
<td>1</td>
</tr>
</tbody>
</table>

Table 1. Eligible ultra-rare disorders

<table>
<thead>
<tr>
<th>Disorder</th>
<th>Eligible ultra-rare disorders</th>
</tr>
</thead>
<tbody>
<tr>
<td>AGU (Aspartylglucosaminuria)</td>
<td>✓</td>
</tr>
<tr>
<td>Fucosidosis</td>
<td>✓</td>
</tr>
<tr>
<td>Geleophysic dysplasia</td>
<td>✓</td>
</tr>
<tr>
<td>GM I Gangliosidosis</td>
<td>✓</td>
</tr>
<tr>
<td>LAL-D (Lysosomal acid lipase deficiency)</td>
<td>✓</td>
</tr>
<tr>
<td>ML I (Mucolipidosis I, Sandhoff disease)</td>
<td>✓</td>
</tr>
<tr>
<td>ML II (Mucolipidosis II, cell disease)</td>
<td>✓</td>
</tr>
<tr>
<td>ML IV (Mucolipidosis IV)</td>
<td>✓</td>
</tr>
<tr>
<td>MLD (Metachromatic leukodystrophy)</td>
<td>✓</td>
</tr>
<tr>
<td>MPS IX (Natowicz)</td>
<td>✓</td>
</tr>
<tr>
<td>MPS VII (Sly)</td>
<td>✓</td>
</tr>
<tr>
<td>MPS IV B</td>
<td>✓</td>
</tr>
<tr>
<td>MSD (Multiple sulfatase deficiency)</td>
<td>✓</td>
</tr>
<tr>
<td>Winchester</td>
<td>✓</td>
</tr>
</tbody>
</table>

Table 2. Ultra-rare disorders of patients included in this study (n=11)

Diagnosis experience

Lack of support during diagnosis delivery:

- Medical language was not clear
  “We did not understand the explanation of the condition”

- Lack of empathy and sympathy
  “Heartless and cold”

- Perceived lack of interest
  “Parents hear their child has a life-limiting condition once, doctors say it every day”

- Insufficient or conflicting information
  “We had to google it”
  “I felt lied to”

Support families and caregivers would have liked around the time of diagnosis:

- Diagnosis explained in lay terms
- Emotional support during and after receiving the diagnosis
- Specialist training for clinicians to deliver it
- Tailored accurate information on the disease, its progression and research
- Information on sources of support and services

Disease journey

The type of care and support that was needed changed as the disease progressed (Figure 1).

Caregivers reported that the most support received around the time of diagnosis was provided by General Practitioners (GP) and the MP Society (Figure 1).

“Our GP was there for life, he was the local point”

The role of specialist centres and community services, such as social workers and hospice teams, became more prominent as the disease progressed (Figure 1).

“The specialist was key to keep us sane”

Caregivers reported receiving emotional support from the MPS Society and international forums, later on in the disease journey

“Without the MPS Society I don’t know where we would be today”

Support families and caregivers would have liked throughout their disease journey:

- Access to counselling services throughout the disease journey and from the point of diagnosis
- Support with paperwork to access services, available help and schooling
- Provision for patients transitioning into adulthood

Conclusions

Caregivers of patients with ultra-rare diseases face constant challenges over time. Providing care and support tailored to different stages of the disease journey is needed to improve the quality of life of patients and their families.

References:

Acknowledgments: This study was made possible by the participation of the membership of The Society for Hurler/Scheie/Hydrops (MPS Society UK) Registered Charity No. 276704. UK.

Research, analysis and medical writing was provided by Dr. Alastair Balfour at Rare Disease Research Partners."